Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial.
Quinn TJ, Daignault-Newton S, Bosch W, Mariados N, Sylvester J, Shah D, Gross E, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, DeWeese T, Gay HA, Michalski J, Hamstra DA. Quinn TJ, et al. Among authors: bosch w. Pract Radiat Oncol. 2020 May-Jun;10(3):186-194. doi: 10.1016/j.prro.2019.12.011. Epub 2020 Jan 21. Pract Radiat Oncol. 2020. PMID: 31978591 Free article. Clinical Trial.
RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
Valicenti RK, Winter K, Cox JD, Sandler HM, Bosch W, Vijayakumar S, Michalski J, Purdy J. Valicenti RK, et al. Among authors: bosch w. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):614-20. doi: 10.1016/s0360-3016(03)00640-0. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529764 Clinical Trial.
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B. Bradley J, et al. Among authors: bosch w. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28. doi: 10.1016/j.ijrobp.2004.06.260. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667949 Clinical Trial.
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C. Michalski JM, et al. Among authors: bosch wr. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8. doi: 10.1016/j.ijrobp.2009.02.006. Epub 2009 Apr 23. Int J Radiat Oncol Biol Phys. 2010. PMID: 19394158 Free PMC article.
Clinical trials and radiation oncology technologies.
Michalski JM, Bosch WR, Purdy JA. Michalski JM, et al. Oncology (Williston Park). 2009 Apr 15;23(4):386, 389. Oncology (Williston Park). 2009. PMID: 19476270 Free article. No abstract available.
Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22).
Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, Sanguineti G, Jones CU, Bosch WR, Ang KK. Eisbruch A, et al. Among authors: bosch wr. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1333-8. doi: 10.1016/j.ijrobp.2009.04.011. Epub 2009 Jun 18. Int J Radiat Oncol Biol Phys. 2010. PMID: 19540060 Free PMC article.
354 results